BioCentury
ARTICLE | Company News

Altacor, Proximagen deal

December 5, 2011 8:00 AM UTC

The companies partnered to develop Proximagen's programs targeting the serotonin (5-HT2C) receptor for ophthalmic indications. Altacor will fund preclinical work of PRX00933, the lead compound under...